8-K: MEI Pharma Prioritizes Voruciclib Development After Promising Trial Results

MEI Pharma is focusing on its voruciclib program after encouraging clinical data, while also advancing a new formulation for ME-344.

Summary

• MEI Pharma reported its third quarter fiscal year 2024 results, highlighting the prioritization of its voruciclib program.
• The company's Phase 1 study of voruciclib combined with venetoclax in relapsed/refractory AML patients showed anti-leukemic activity, including complete responses.
• Initial results showed anticipated decreases in Mcl-1, a protein associated with resistance to venetoclax, with no overlapping toxicity observed.
• MEI has decided to advance ME-344 through a new formulation rather than adding a new cohort to the current study, aiming to increase biological activity and improve administration.
• The company ended the quarter with $56.6 million in cash and has reduced its operating expenses compared to the previous year.
• MEI believes its current cash balance is sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data for voruciclib and a strong cash position. However, the lack of revenue and the risks associated with drug development temper the overall sentiment.

Positives

• The voruciclib program is showing promising clinical results, including complete responses in a difficult-to-treat patient population.
• The combination of voruciclib and venetoclax appears to be well-tolerated with no overlapping toxicities.
• The company has a strong cash position of $56.6 million, which is expected to fund operations for at least the next 12 months.
• Operating expenses have decreased, indicating improved financial management.
• The company is actively working on a new formulation for ME-344 to improve its biological activity and commercial potential.

Negatives

• MEI recognized no revenue for the quarter ended March 31, 2024, compared to $5.9 million for the same quarter in 2023, due to the termination of the Kyowa Kirin agreement.
• The company has decided not to proceed with a second return of capital under the Anson Funds and Cable Car Capital cooperation agreement.

Risks

• The company's success is heavily dependent on the clinical development and regulatory approval of its drug candidates.
• Clinical trial results may differ from reported interim data.
• There are risks associated with the company's dependence on collaboration or contractual arrangements.
• The company faces competition from other pharmaceutical companies.
• The company may not be able to protect its patents or proprietary rights.
• The company may need to obtain additional financing in the future.
• There are risks associated with general economic conditions, geopolitical conflicts, and activist investors.

Future Outlook

MEI expects to report clinical data from additional dose escalation and expansion cohorts of the ongoing Phase 1 clinical trial evaluating voruciclib plus venetoclax in patients with R/R AML during the remainder of calendar 2024. The company also expects to provide an update on its ME-344 formulation efforts in the first half of calendar 2025.

Management Comments

• David Urso, president and chief executive officer of MEI Pharma, stated that the company has received encouraging clinical data for voruciclib and ME-344.
• Mr. Urso also mentioned that the clinical focus for the rest of the year will be voruciclib, their oral CDK9 inhibitor.
• Mr. Urso believes that voruciclib in combination with venetoclax has the potential to benefit the largest number of patients with relapsed/refractory AML.

Industry Context

The focus on voruciclib, a CDK9 inhibitor, aligns with the industry's interest in novel therapies that can overcome resistance to standard treatments like venetoclax in AML. The development of a new formulation for ME-344 also reflects the industry's push for improved drug delivery and efficacy.

Comparison to Industry Standards

• The reported complete responses in the voruciclib trial are encouraging, as many AML treatments struggle to achieve such results in heavily pretreated patients. Companies like AbbVie (Venclexta) and others developing targeted therapies for AML are constantly seeking to improve outcomes.
• The observed decrease in Mcl-1 levels is significant, as Mcl-1 is a known resistance mechanism to venetoclax. This suggests that voruciclib could address a critical unmet need in AML treatment.
• The decision to prioritize voruciclib and develop a new formulation for ME-344 is a strategic move to focus resources on the most promising programs, which is a common practice in the biotech industry. Many companies, such as Agios Pharmaceuticals and Kura Oncology, have made similar strategic decisions to focus on their lead assets.
• The cash runway of at least 12 months is a positive sign, as many biotech companies face funding challenges. This is comparable to other companies of similar size and stage, such as Xencor and Blueprint Medicines, which also prioritize maintaining a strong cash position.

Stakeholder Impact

• Shareholders may view the prioritization of voruciclib and the positive clinical data as encouraging.
• Employees may be impacted by the company's strategic decisions and resource allocation.
• Patients with relapsed/refractory AML may benefit from the development of voruciclib.
• The company's financial stability may impact its suppliers and creditors.

Next Steps

• MEI expects to report clinical data from additional dose escalation and expansion cohorts of the ongoing Phase 1 clinical trial evaluating voruciclib plus venetoclax during the remainder of calendar 2024.
• The company will continue research and development activity of a new ME-344 formulation.
• MEI expects to provide an update on its formulation efforts in the first half of calendar 2025.

Key Dates

Keywords

Voruciclib, ME-344, AML, CDK9 inhibitor, Venetoclax, Mcl-1, Oncology, Clinical Trials, Pharmaceutical, R/R AML